Cargando…

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C–C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C–C chemokine receptor typ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okamoto, Mika, Toyama, Masaaki, Baba, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392080/ https://www.ncbi.nlm.nih.gov/pubmed/32739404 http://dx.doi.org/10.1016/j.antiviral.2020.104902

Ejemplares similares

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022)

SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A NIGELLA SATIVA SEED FORMULATION
por: Oyero, Olufunmilayo G., et al.
Publicado: (2016)

The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmd(mdx-4Cv)) mice
por: Liang, Feng, et al.
Publicado: (2018)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

A novel tetramethylnaphthalene derivative synergistically inhibits HTLV-1-infected cell proliferation in combination with cepharanthine
por: Toyama, Masaaki, et al.
Publicado: (2011)

Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy
por: Kwiatkowski, Klaudia, et al.
Publicado: (2020)

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
por: Visseaux, Benoit, et al.
Publicado: (2015)

Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors
por: Baba, Masanori, et al.
Publicado: (2017)

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
por: Eksteen, Bertus, et al.
Publicado: (2020)

Methylene blue inhibits replication of SARS-CoV-2 in vitro
por: Gendrot, Mathieu, et al.
Publicado: (2020)

Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”
por: Caruso, Arnaldo, et al.
Publicado: (2020)

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
por: Murray, Jackelyn, et al.
Publicado: (2021)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
por: Wang, Zheng, et al.
Publicado: (2019)

Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation
por: Gendrot, Mathieu, et al.
Publicado: (2020)

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
por: Thompson, Melanie, et al.
Publicado: (2016)

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
por: Caly, Leon, et al.
Publicado: (2020)

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
por: Choy, Ka-Tim, et al.
Publicado: (2020)

Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
por: Morokutti-Kurz, Martina, et al.
Publicado: (2021)

Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures
por: Martina, Zafferani, et al.
Publicado: (2020)

Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures
por: Zafferani, Martina, et al.
Publicado: (2021)

Promising Modulatory Effects of Cenicriviroc on the Progression of Mouse Colorectal Cancer through Inhibition of CCR2_CCL2 Signaling Pathway
por: Eslami, Mina, et al.
Publicado: (2023)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication
por: Klann, Kevin, et al.
Publicado: (2020)

Aprotinin Inhibits SARS-CoV-2 Replication
por: Bojkova, Denisa, et al.
Publicado: (2020)

Inhibition of SARS-CoV replication by siRNA
por: Wu, Chang-Jer, et al.
Publicado: (2005)

Novel amodiaquine derivatives potently inhibit Ebola virus infection
por: Sakurai, Yasuteru, et al.
Publicado: (2018)

Exploring Novel Vitamin K Derivatives with Anti-SARS-CoV-2 Activity
por: Homma, Taiki, et al.
Publicado: (2023)

Gaseous nitric oxide failed to inhibit the replication cycle of SARS-CoV-2 in vitro
por: Rousseaud, Audrey, et al.
Publicado: (2023)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2021)

Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists
por: Zheng, Yi, et al.
Publicado: (2016)

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
por: Diaz Soto, Maria Paula, et al.
Publicado: (2020)

Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro
por: Salas Rojas, Mónica, et al.
Publicado: (2021)

Chemokines and chemokine receptors as promising targets in rheumatoid arthritis
por: Murayama, Masanori A., et al.
Publicado: (2023)

Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro
por: Akaberi, Dario, et al.
Publicado: (2020)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis
por: Sun, Zhe, et al.
Publicado: (2011)

Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?
por: Javor, S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_094n8ldni9i8sd1du70es16a05